Shanghai Bio-heart Biological Technology Co., Ltd.
HKSE: 2185.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Li Wang
- Employees
- 63
- Headquarters
- Shanghai, China
- IPO year
- 2021
- Market cap
- HK$1.1B
- Website
- https://www.bio-heart.com
Loading 2185…
Loading profile data…Frequently asked questions about 2185
What does Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK) do?
Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. The company focuses on the provision of bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies for the treatment of coronary artery diseases and uncontrolled and resistant hypertension. It...
Where does 2185.HK trade?
Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK) trades on the Hong Kong Stock Exchange.
What sector is 2185.HK in?
Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Shanghai Bio-heart Biological Technology Co., Ltd.?
Li Wang is the chief executive officer of Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK).
Where is Shanghai Bio-heart Biological Technology Co., Ltd. headquartered?
Shanghai Bio-heart Biological Technology Co., Ltd. is headquartered in China.
Does 2185.HK pay a dividend?
Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2185.HK go public?
Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK) completed its initial public offering in 2021.